Ganciclovir-Resistant CMV Colitis in a Donor-Seronegative/Recipient-Seronegative Liver Transplant Patient | Zendy

Samuel Igbinedion | Zendy; Krunal Patel | Zendy; Hrishikesh Samant | Zendy; Gregory P. Wellman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ganciclovir-Resistant CMV Colitis in a Donor-Seronegative/Recipient-Seronegative Liver Transplant Patient

Author(s) -

Samuel Igbinedion,

Krunal Patel,

Hrishikesh Samant,

Gregory P. Wellman

Publication year - 2018

Publication title -

acg case reports journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.112

H-Index - 4

ISSN - 2326-3253

DOI - 10.14309/crj.2018.102

Subject(s) - valganciclovir , medicine , ganciclovir , cytomegalovirus , liver transplantation , population , disease , liver disease , immunology , gastroenterology , transplantation , human cytomegalovirus , herpesviridae , virus , viral disease , environmental health

Cytomegalovirus (CMV) disease in liver transplant patients with donor-seronegative and recipient-seronegative (D-/R-) status is a rarity. Ganciclovir-resistant CMV disease in this population has not been reported in the literature. We present a 62-year-old man who underwent orthotopic liver transplant from a cadaveric donor. The patient's status was CMV D-/R-, and he had completed 90 days of valganciclovir therapy for CMV prophylaxis, yet he developed CMV disease. We highlight the danger of the liberal use of CMV prophylaxis in this subset of the liver transplant population. To our knowledge, this is the first report of ganciclovir-resistant (GanR) CMV disease in a liver transplant patient with CMV D-/R- status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research